04.11.2025
Adcock Ingram delisting from the JSE is confirmed for November 11. Learn about the impact of the Natco Pharma acquisition.
16.09.2025
Ascendis to delist from the JSE as part of its strategy to go private, aiming for operational freedom and agility.
24.08.2025
Adcock Ingram reports steady annual profits as winter demand for Panado and Corenza-C drives growth in the second half.